Kane BiotechKNBIF +5.19% EV-to-FCF is -2.84 as of Jun. 24, 2026. The stock has 6 warning signs investors should review. Among 328 Biotechnology companies, Kane Biotech ranks worse than 304877.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kane Biotech's Enterprise Value is $5.64 Mil.
Kane Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.99 Mil. Therefore, Kane Biotech's EV-to-FCF for today is -2.84.
The historical rank and industry rank for Kane Biotech's EV-to-FCF or its related term are showing as below:
KNBIF'
s EV-to-FCF Range Over the Past 10 Years
Min: -34.93 Med: -4.76 Max: -1.02
Current: -2.84
During the past 13 years, the highest EV-to-FCF of Kane Biotech was -1.02. The lowest was -34.93. And the median was -4.76.
KNBIF's EV-to-FCF is ranked worse than 100% of 328
companies
in the Biotechnology industry
Industry Median: 14.86
vs KNBIF: -2.84
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kane Biotech's PE Ratio (TTM) for today is calculated as:
Kane Biotech's share price for today is $0.0215.
Kane Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kane Biotech EV-to-FCF Related Terms
Kane Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Kane Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kane Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kane Biotech's EV-to-FCF falls into.
Kane Biotech's current Enterprise Value is $5.64 Mil.
Kane Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a EV-to-FCF of -2.84 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kane Biotech and its competitors. According to the industry distribution chart, Kane Biotech ranks #999999 out of 328 companies in the Biotechnology industry.
Is Kane Biotech's EV-to-FCF too high?
Kane Biotech's current EV-to-FCF is -2.84. Based on the distribution chart, Kane Biotech ranks #999999 out of 328 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #999999 out of 328 companies for EV-to-FCF. This places Kane Biotech in the lower half of its industry. The industry median EV-to-FCF is 14.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.86, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current EV-to-FCF is -2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current EV-to-FCF of -2.84. The current EV-to-FCF is -2.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current EV-to-FCF is -2.84 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 